| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects (NCT02479022) | Novo Nordisk A/S | 2015-06-01 |
| A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam (NCT02066766) | Novo Nordisk A/S | 2015-04-22 |
| Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial (NCT02541942) | Novo Nordisk A/S | 2015-04-03 |
| Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice (NCT02255266) | Novo Nordisk A/S | 2015-03-26 |
| Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus (NCT02392117) | Novo Nordisk A/S | 2015-03-16 |
| A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency (NCT02382939) | Novo Nordisk A/S | 2015-02-12 |
| Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants (NCT02608853) | Novo Nordisk A/S | 2015-01-01 |
| Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®) (NCT02321878) | Novo Nordisk A/S | 2014-12-15 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes (NCT02305381) | Novo Nordisk A/S | 2014-12-01 |
| Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects (NCT02300844) | Novo Nordisk A/S | 2014-12-01 |
| Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects (NCT02304627) | Novo Nordisk A/S | 2014-11-24 |
| A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms (NCT02298192) | Novo Nordisk A/S | 2014-11-21 |
| To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (NCT02241694) | Novo Nordisk A/S | 2014-11-01 |
| Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (NCT02229851) | Novo Nordisk A/S | 2014-10-31 |
| A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes (NCT02306681) | Novo Nordisk A/S | 2014-10-30 |
| A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan (NCT01876745) | Novo Nordisk A/S | 2014-10-07 |
| A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (NCT02254291) | Novo Nordisk A/S | 2014-10-02 |
| A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka (NCT01957592) | Novo Nordisk A/S | 2014-10-01 |
| A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (NCT02230631) | Novo Nordisk A/S | 2014-10-01 |
| Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (NCT02249871) | Novo Nordisk A/S | 2014-09-24 |
| Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects (NCT02249910) | Novo Nordisk A/S | 2014-09-18 |
| Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects (NCT02243098) | Novo Nordisk A/S | 2014-09-16 |
| Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects (NCT02235961) | Novo Nordisk A/S | 2014-09-04 |
| A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (NCT02097264) | Novo Nordisk A/S | 2014-09-01 |
| Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide (NCT02231684) | Novo Nordisk A/S | 2014-09-01 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus (NCT02220296) | Novo Nordisk A/S | 2014-08-20 |
| A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (NCT02205528) | Novo Nordisk A/S | 2014-08-18 |
| A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes (NCT02212067) | Novo Nordisk A/S | 2014-08-11 |
| Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function (NCT02210871) | Novo Nordisk A/S | 2014-08-07 |
| A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (NCT02207374) | Novo Nordisk A/S | 2014-08-04 |
| To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan (NCT02207218) | Novo Nordisk A/S | 2014-08-04 |
| Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (NCT02128932) | Novo Nordisk A/S | 2014-08-04 |
| Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors (NCT02207348) | Novo Nordisk A/S | 2014-08-01 |
| Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B (NCT02141074) | Novo Nordisk A/S | 2014-07-02 |
| Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (NCT02137850) | Novo Nordisk A/S | 2014-06-26 |
| A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (NCT02131272) | Novo Nordisk A/S | 2014-06-11 |
| Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (NCT02035384) | Novo Nordisk A/S | 2014-06-05 |
| Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects (NCT02172313) | Novo Nordisk A/S | 2014-06-01 |
| A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects (NCT02161588) | Novo Nordisk A/S | 2014-06-01 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes (NCT02148861) | Novo Nordisk A/S | 2014-05-26 |
| A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes (NCT02147431) | Novo Nordisk A/S | 2014-05-21 |
| A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects (NCT02146079) | Novo Nordisk A/S | 2014-05-21 |
| A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (NCT02131246) | Novo Nordisk A/S | 2014-05-01 |
| The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (NCT02098395) | Novo Nordisk A/S | 2014-05-01 |
| A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (NCT02100475) | Novo Nordisk A/S | 2014-04-01 |
| A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects (NCT02089451) | Novo Nordisk A/S | 2014-03-17 |
| Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo (NCT02079870) | Novo Nordisk A/S | 2014-03-06 |
| Project to Update the Study of Congenital Haemophilia in Spain (NCT01959555) | Novo Nordisk A/S | 2014-03-01 |
| Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) (NCT02005198) | Novo Nordisk A/S | 2014-03-01 |
| Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects (NCT02084810) | Novo Nordisk A/S | 2014-03-01 |
| Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects (NCT02094521) | Novo Nordisk A/S | 2014-03-01 |
| A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects (NCT02070510) | Novo Nordisk A/S | 2014-02-27 |
| A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects (NCT02064348) | Novo Nordisk A/S | 2014-02-26 |
| A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden (NCT02077946) | Novo Nordisk A/S | 2014-02-10 |
| Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects (NCT02060266) | Novo Nordisk A/S | 2014-02-04 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (NCT02054897) | Novo Nordisk A/S | 2014-02-03 |
| A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (NCT02035371) | Novo Nordisk A/S | 2014-01-13 |
| Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes (NCT01917656) | Novo Nordisk A/S | 2014-01-09 |
| A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (NCT02030600) | Novo Nordisk A/S | 2014-01-06 |
| A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (NCT02034513) | Novo Nordisk A/S | 2014-01-05 |
| A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (NCT02033239) | Novo Nordisk A/S | 2014-01-01 |
| Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects (NCT02022254) | Novo Nordisk A/S | 2013-12-17 |
| A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency (NCT01973244) | Novo Nordisk A/S | 2013-12-16 |
| Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment (NCT02016911) | Novo Nordisk A/S | 2013-12-12 |
| Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function (NCT02014259) | Novo Nordisk A/S | 2013-12-11 |
| Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes (NCT01923181) | Novo Nordisk A/S | 2013-12-02 |
| Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (NCT01907854) | Novo Nordisk A/S | 2013-12-02 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (NCT01930188) | Novo Nordisk A/S | 2013-12-02 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (NCT01885208) | Novo Nordisk A/S | 2013-12-02 |
| The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes (NCT02008682) | Novo Nordisk A/S | 2013-12-01 |
| A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (NCT02003677) | Novo Nordisk A/S | 2013-11-29 |
| Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus (NCT01821846) | Novo Nordisk A/S | 2013-11-20 |
| A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (NCT01999322) | Novo Nordisk A/S | 2013-11-19 |
| Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba® (NCT01984372) | Novo Nordisk A/S | 2013-11-06 |
| Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects (NCT01978613) | Novo Nordisk A/S | 2013-11-01 |
| A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes (NCT01992588) | Novo Nordisk A/S | 2013-11-01 |
| The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (NCT01836523) | Novo Nordisk A/S | 2013-11-01 |
| A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (NCT01959529) | Novo Nordisk A/S | 2013-10-29 |
| A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus (NCT01835431) | Novo Nordisk A/S | 2013-10-17 |
| Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes (NCT01973231) | Novo Nordisk A/S | 2013-10-01 |
| Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (NCT01988532) | Novo Nordisk A/S | 2013-10-01 |
| Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects (NCT01967589) | Novo Nordisk A/S | 2013-10-01 |
| An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry (NCT01892319) | Novo Nordisk A/S | 2013-09-30 |
| Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (NCT01850615) | Novo Nordisk A/S | 2013-09-23 |
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (NCT01952145) | Novo Nordisk A/S | 2013-09-20 |
| Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (NCT01819129) | Novo Nordisk A/S | 2013-09-09 |
| A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors (NCT01949792) | Novo Nordisk A/S | 2013-09-01 |
| A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis (NCT01955603) | Novo Nordisk A/S | 2013-09-01 |
| A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects (NCT01943084) | Novo Nordisk A/S | 2013-09-01 |
| A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia (NCT01934673) | Novo Nordisk A/S | 2013-09-01 |
| A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia (NCT01934686) | Novo Nordisk A/S | 2013-09-01 |
| A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes (NCT01934712) | Novo Nordisk A/S | 2013-08-30 |
| Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (NCT01831765) | Novo Nordisk A/S | 2013-08-26 |
| Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome (NCT01927861) | Novo Nordisk A/S | 2013-08-19 |
| A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes (NCT01924637) | Novo Nordisk A/S | 2013-08-01 |
| Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe (NCT01890993) | Novo Nordisk A/S | 2013-08-01 |
| Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers (NCT01512095) | Novo Nordisk A/S | 2013-08-01 |
| A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects (NCT01916174) | Novo Nordisk A/S | 2013-08-01 |
| A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects (NCT01931137) | Novo Nordisk A/S | 2013-08-01 |
| Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period (NCT01900834) | Novo Nordisk A/S | 2013-07-01 |